Clinical significance of microvessel density in multiple myeloma patients

Myung‐Ju Ahn(Sungkyunkwan University), Moran Ki(National Cancer Center), Chan Kum Park(Hanyang University), Won Mee Lee(Hanyang University), Il Young Choi(Hanyang University), Jung Hye Choi(Hanyang University Guri Hospital), In Soon Kim(Hanyang University), Woong Soo Lee(Hanyang University), Young Yeul Lee(Hanyang University)

Journal of Korean Medical Science

January 1, 2001

10.3346/jkms.2001.16.1.45

Cited by 20

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537